{"name":"Bristol-Myers Squibb","slug":"bms","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":41180000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Eliquis","genericName":"apixaban","slug":"apixaban","revenue":14443000000,"yoyGrowth":0,"percentOfTotal":35.1},{"name":"Opdivo","genericName":"nivolumab","slug":"nivolumab","revenue":9200000000,"yoyGrowth":0,"percentOfTotal":22.3},{"name":"Revlimid","genericName":"lenalidomide","slug":"lenalidomide","revenue":5809000000,"yoyGrowth":0,"percentOfTotal":14.1},{"name":"Orencia","genericName":"abatacept","slug":"abatacept","revenue":3705000000,"yoyGrowth":0,"percentOfTotal":9},{"name":"Yervoy","genericName":"ipilimumab","slug":"ipilimumab","revenue":2900000000,"yoyGrowth":0,"percentOfTotal":7},{"name":"Pomalyst","genericName":"pomalidomide","slug":"pomalidomide","revenue":2800000000,"yoyGrowth":0,"percentOfTotal":6.8},{"name":"Zeposia","genericName":"OZANIMOD","slug":"ozanimod","revenue":800000000,"yoyGrowth":0,"percentOfTotal":1.9},{"name":"Camzyos","genericName":"MAVACAMTEN","slug":"mavacamten","revenue":600000000,"yoyGrowth":0,"percentOfTotal":1.5},{"name":"Abecma","genericName":"idecabtagene vicleucel","slug":"idecabtagene-vicleucel","revenue":427000000,"yoyGrowth":0,"percentOfTotal":1},{"name":"Sotyktu","genericName":"DEUCRAVACITINIB","slug":"deucravacitinib","revenue":291000000,"yoyGrowth":0,"percentOfTotal":0.7},{"name":"Krazati","genericName":"ADAGRASIB","slug":"adagrasib","revenue":205000000,"yoyGrowth":0,"percentOfTotal":0.5}],"timeline":[{"date":"1945-01-01","label":"Dextrotubocurarine Chloride first approved","drug":"Dextrotubocurarine Chloride","drugSlug":"tubocurarine","type":"approval","sentiment":"positive"},{"date":"1963-01-01","label":"Acetadote first approved","drug":"Acetadote","drugSlug":"acetylcysteine","type":"approval","sentiment":"positive"},{"date":"1965-01-01","label":"Unasyn first approved","drug":"Unasyn","drugSlug":"ampicillin","type":"approval","sentiment":"positive"},{"date":"1967-01-01","label":"Moditen Enanthate first approved","drug":"Moditen Enanthate","drugSlug":"fluphenazine-enanthate","type":"approval","sentiment":"positive"},{"date":"1971-01-01","label":"Megace first approved","drug":"Megace","drugSlug":"megestrol-acetate","type":"approval","sentiment":"positive"},{"date":"1972-01-01","label":"Prolixin Decanoate first approved","drug":"Prolixin Decanoate","drugSlug":"fluphenazine-decanoate","type":"approval","sentiment":"positive"},{"date":"1973-01-01","label":"Kanacin first approved","drug":"Kanacin","drugSlug":"kanamycin","type":"approval","sentiment":"positive"},{"date":"1973-01-01","label":"Blenoxane first approved","drug":"Blenoxane","drugSlug":"bleomycin","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Cefaprin first approved","drug":"Cefaprin","drugSlug":"cefapirin","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Cefradex first approved","drug":"Cefradex","drugSlug":"cefradine","type":"approval","sentiment":"positive"},{"date":"1975-01-01","label":"Delalutin first approved","drug":"Delalutin","drugSlug":"hydroxyprogesterone-caproate","type":"approval","sentiment":"positive"},{"date":"1981-01-01","label":"Arikayce Kit first approved","drug":"Arikayce Kit","drugSlug":"amikacin","type":"approval","sentiment":"positive"},{"date":"1983-01-01","label":"Vepesid first approved","drug":"Vepesid","drugSlug":"etoposide","type":"approval","sentiment":"positive"},{"date":"1986-01-01","label":"Azactam first approved","drug":"Azactam","drugSlug":"aztreonam","type":"approval","sentiment":"positive"},{"date":"1991-01-01","label":"Videx first approved","drug":"Videx","drugSlug":"didanosine","type":"approval","sentiment":"positive"},{"date":"1994-01-01","label":"Serzone first approved","drug":"Serzone","drugSlug":"nefazodone","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Sustiva first approved","drug":"Sustiva","drugSlug":"efavirenz","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Thalomid first approved","drug":"Thalomid","drugSlug":"thalidomide","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Reyataz first approved","drug":"Reyataz","drugSlug":"atazanavir","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Vidaza first approved","drug":"Vidaza","drugSlug":"azacitidine","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Revlimid first approved","drug":"Revlimid","drugSlug":"lenalidomide","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Orencia first approved","drug":"Orencia","drugSlug":"abatacept","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Baraclude first approved","drug":"Baraclude","drugSlug":"entecavir","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Yervoy first approved","drug":"Yervoy","drugSlug":"ipilimumab","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Nulojix first approved","drug":"Nulojix","drugSlug":"belatacept","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Eliquis first approved","drug":"Eliquis","drugSlug":"apixaban","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Pomalyst first approved","drug":"Pomalyst","drugSlug":"pomalidomide","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Opdivo first approved","drug":"Opdivo","drugSlug":"nivolumab","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Huluc63 first approved","drug":"Huluc63","drugSlug":"elotuzumab","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Daklinza first approved","drug":"Daklinza","drugSlug":"daclatasvir","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Idhifa first approved","drug":"Idhifa","drugSlug":"enasidenib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Inrebic first approved","drug":"Inrebic","drugSlug":"fedratinib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Inrebic first approved","drug":"Inrebic","drugSlug":"fedratinib-hydrochloride","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Zeposia first approved","drug":"Zeposia","drugSlug":"ozanimod","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Camzyos first approved","drug":"Camzyos","drugSlug":"mavacamten","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Sotyktu first approved","drug":"Sotyktu","drugSlug":"deucravacitinib","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Krazati first approved","drug":"Krazati","drugSlug":"adagrasib","type":"approval","sentiment":"positive"},{"date":"2026-05-21","label":"Acetadote patent expiry (Formulation)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"Krazati PHASE1,PHASE2 readout","drug":"Krazati","drugSlug":"adagrasib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-05-14","label":"Vidaza patent expiry (Method of Use)","drug":"Vidaza","drugSlug":"azacitidine","type":"patent_expiry","sentiment":"negative"},{"date":"2029-05-14","label":"Vidaza patent expiry (Formulation)","drug":"Vidaza","drugSlug":"azacitidine","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-03","label":"Vidaza patent expiry (Formulation)","drug":"Vidaza","drugSlug":"azacitidine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-02-24","label":"Eliquis patent expiry (Formulation)","drug":"Eliquis","drugSlug":"apixaban","type":"patent_expiry","sentiment":"negative"},{"date":"2031-07-21","label":"Acetadote patent expiry (Method of Use)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-08-24","label":"Eliquis patent expiry (Compound)","drug":"Eliquis","drugSlug":"apixaban","type":"patent_expiry","sentiment":"negative"},{"date":"2032-04-06","label":"Acetadote patent expiry (Method of Use)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-05-08","label":"Acetadote patent expiry (Formulation)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-05-08","label":"Acetadote patent expiry (Method of Use)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-05-08","label":"Acetadote patent expiry (Formulation)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2034-01-31","label":"OPDIVO QVANTIG Phase 3 readout (Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma)","drug":"OPDIVO QVANTIG","drugSlug":"hyaluronidase-nvhy","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":20914000000,"percentOfTotal":50.8,"drugCount":38,"colorKey":"immunology","drugs":[{"name":"Opdivo","genericName":"nivolumab","slug":"nivolumab","indication":"Advanced melanoma with tumour cell PD-L1 expression below 1%","status":"marketed","revenue":9200000000},{"name":"Revlimid","genericName":"lenalidomide","slug":"lenalidomide","indication":"Follicular lymphoma","status":"marketed","revenue":5809000000},{"name":"Yervoy","genericName":"ipilimumab","slug":"ipilimumab","indication":"High grade squamous intraepithelial neoplasia of esophagus","status":"discontinued","revenue":2900000000},{"name":"Pomalyst","genericName":"pomalidomide","slug":"pomalidomide","indication":"Multiple myeloma","status":"marketed","revenue":2800000000},{"name":"Krazati","genericName":"ADAGRASIB","slug":"adagrasib","indication":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","status":"marketed","revenue":205000000},{"name":"Huluc63","genericName":"elotuzumab","slug":"elotuzumab","indication":"Multiple myeloma","status":"marketed"},{"name":"Vidaza","genericName":"azacitidine","slug":"azacitidine","indication":"Refractory Anemia (RA)","status":"marketed"},{"name":"Vepesid","genericName":"etoposide","slug":"etoposide","indication":"Malignant tumor of testis","status":"marketed"},{"name":"BMS-986231","genericName":"BMS-986231","slug":"bms-986231","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BMS-986374","genericName":"BMS-986374","slug":"bms-986374","indication":"Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion","status":"marketed"},{"name":"Blenoxane","genericName":"BLEOMYCIN","slug":"bleomycin","indication":"Diffuse non-Hodgkin's lymphoma, large cell","status":"marketed"},{"name":"Immunotherapy monotherapy","genericName":"Immunotherapy monotherapy","slug":"immunotherapy-monotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"ABA, open-label (OL)","genericName":"ABA, open-label (OL)","slug":"aba-open-label-ol","indication":"Metastatic melanoma","status":"phase_3"},{"name":"BET Inhibitor","genericName":"BET Inhibitor","slug":"bet-inhibitor","indication":"T-cell lymphoma","status":"phase_2"},{"name":"BMS-650032","genericName":"BMS-650032","slug":"bms-650032","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-790052","genericName":"BMS-790052","slug":"bms-790052","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-936558 (Nivolumab)","genericName":"BMS-936558 (Nivolumab)","slug":"bms-936558-nivolumab","indication":"Metastatic melanoma","status":"phase_3"},{"name":"BMS-954561","genericName":"BMS-954561","slug":"bms-954561","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"BMS-986165 Dose A","genericName":"BMS-986165 Dose A","slug":"bms-986165-dose-a","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-986165 Dose B","genericName":"BMS-986165 Dose B","slug":"bms-986165-dose-b","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-986177","genericName":"BMS-986177","slug":"bms-986177","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BMS-986504","genericName":"BMS-986504","slug":"bms-986504","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"Carboplatin/Paraplatin","genericName":"Carboplatin/Paraplatin","slug":"carboplatin-paraplatin","indication":"Ovarian cancer","status":"phase_3"},{"name":"Cetuximab/Erbitux","genericName":"Cetuximab/Erbitux","slug":"cetuximab-erbitux","indication":"Metastatic colorectal cancer (KRAS wild-type)","status":"phase_3"},{"name":"Cisplatin/Platinol","genericName":"Cisplatin/Platinol","slug":"cisplatin-platinol","indication":"Metastatic testicular cancer","status":"phase_3"},{"name":"Corticosteroid: Meprednisone","genericName":"Corticosteroid: Meprednisone","slug":"corticosteroid-meprednisone","indication":"Treatment of various cancers","status":"phase_2"},{"name":"Fluorouracil/Adrucil","genericName":"Fluorouracil/Adrucil","slug":"fluorouracil-adrucil","indication":"Colorectal cancer","status":"phase_3"},{"name":"Idhifa","genericName":"ENASIDENIB","slug":"enasidenib","indication":"Acute myeloid leukemia, disease","status":"marketed"},{"name":"Megace","genericName":"MEGESTROL ACETATE","slug":"megestrol-acetate","indication":"Anorexia from HIV","status":"marketed"},{"name":"NKTR-214","genericName":"NKTR-214","slug":"nktr-214","indication":"Metastatic melanoma (in combination with nivolumab)","status":"phase_3"},{"name":"Nivolumab and rHuPH20","genericName":"Nivolumab and rHuPH20","slug":"nivolumab-and-rhuph20","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Nivolumab in combination with Ipilimumab","genericName":"Nivolumab in combination with Ipilimumab","slug":"nivolumab-in-combination-with-ipilimumab","indication":"Metastatic melanoma","status":"marketed"},{"name":"Nivolumab-relatlimab FDC","genericName":"Nivolumab-relatlimab FDC","slug":"nivolumab-relatlimab-fdc","indication":"Melanoma (advanced or metastatic)","status":"phase_3"},{"name":"Nivolumab/rHuPH20","genericName":"Nivolumab/rHuPH20","slug":"nivolumab-rhuph20","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Placebo for Ipilimumab","genericName":"Placebo for Ipilimumab","slug":"placebo-for-ipilimumab","indication":"Metastatic melanoma","status":"phase_3"},{"name":"SAR302503","genericName":"SAR302503","slug":"sar302503","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Thalomid","genericName":"THALIDOMIDE","slug":"thalidomide","indication":"Newly Diagnosed Multiple Myeloma","status":"marketed"},{"name":"Yervoy","genericName":"Yervoy","slug":"yervoy","indication":"High grade squamous intraepithelial neoplasia of esophagus","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":15043000000,"percentOfTotal":36.5,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"Eliquis","genericName":"apixaban","slug":"apixaban","indication":"Arterial embolus and thrombosis","status":"marketed","revenue":14443000000},{"name":"Camzyos","genericName":"MAVACAMTEN","slug":"mavacamten","indication":"Obstructive hypertrophic cardiomyopathy (HCM)","status":"marketed","revenue":600000000},{"name":"Ramipril + Irbesartan","genericName":"Ramipril + Irbesartan","slug":"ramipril-irbesartan","indication":"Hypertension in patients not adequately controlled on monotherapy","status":"marketed"},{"name":"BMS-986205","genericName":"BMS-986205","slug":"bms-986205","indication":"Acute coronary syndrome","status":"phase_3"},{"name":"Inrebic","genericName":"FEDRATINIB","slug":"fedratinib","indication":"Myelofibrosis","status":"marketed"},{"name":"Approved Hypertrophic Cardiomyopathy drug treatments","genericName":"Approved Hypertrophic Cardiomyopathy drug treatments","slug":"approved-hypertrophic-cardiomyopathy-drug-treatments","indication":"Hypertrophic cardiomyopathy","status":"phase_2"},{"name":"BMS-986278","genericName":"BMS-986278","slug":"bms-986278","indication":"Acute coronary syndrome","status":"phase_3"},{"name":"HCTZ monotherapy","genericName":"HCTZ monotherapy","slug":"hctz-monotherapy","indication":"Hypertension","status":"phase_3"},{"name":"Inrebic","genericName":"FEDRATINIB HYDROCHLORIDE","slug":"fedratinib-hydrochloride","indication":"Myelofibrosis","status":"marketed"},{"name":"Irbesartan monotherapy","genericName":"Irbesartan monotherapy","slug":"irbesartan-monotherapy","indication":"Hypertension","status":"phase_3"},{"name":"Irbesartan/HCTZ","genericName":"Irbesartan/HCTZ","slug":"irbesartan-hctz","indication":"Hypertension (high blood pressure)","status":"phase_3"},{"name":"Nitroglycerin (NTG)","genericName":"Nitroglycerin (NTG)","slug":"nitroglycerin-ntg","indication":"Acute angina pectoris (sublingual/spray formulation)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":4796000000,"percentOfTotal":11.6,"drugCount":25,"colorKey":"cardiovascular","drugs":[{"name":"Orencia","genericName":"abatacept","slug":"abatacept","indication":"Juvenile idiopathic arthritis","status":"marketed","revenue":3705000000},{"name":"Zeposia","genericName":"OZANIMOD","slug":"ozanimod","indication":"Multiple sclerosis","status":"marketed","revenue":800000000},{"name":"Sotyktu","genericName":"DEUCRAVACITINIB","slug":"deucravacitinib","indication":"Moderate-to-severe plaque psoriasis","status":"marketed","revenue":291000000},{"name":"BMS-986165","genericName":"BMS-986165","slug":"bms-986165","indication":"Psoriasis","status":"marketed"},{"name":"Abatacept subcutaneous","genericName":"Abatacept subcutaneous","slug":"abatacept-subcutaneous","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Anti-IL8","genericName":"Anti-IL8","slug":"anti-il8","indication":"Moderate to severe chronic plaque psoriasis","status":"phase_2"},{"name":"Anti-IP-10 Antibody","genericName":"Anti-IP-10 Antibody","slug":"anti-ip-10-antibody","indication":"Psoriasis","status":"phase_2"},{"name":"Any biologic treatment for psoriasis","genericName":"Any biologic treatment for psoriasis","slug":"any-biologic-treatment-for-psoriasis","indication":"Moderate to severe plaque psoriasis","status":"phase_2"},{"name":"Corticosteroid: Methylprednisolone","genericName":"Corticosteroid: Methylprednisolone","slug":"corticosteroid-methylprednisolone","indication":"Multiple sclerosis","status":"phase_2"},{"name":"Corticosteroid: Prednisone","genericName":"Corticosteroid: Prednisone","slug":"corticosteroid-prednisone","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"Double-blind Abatacept","genericName":"Double-blind Abatacept","slug":"double-blind-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Infliximab (INF) + MTX, DB","genericName":"Infliximab (INF) + MTX, DB","slug":"infliximab-inf-mtx-db","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Intravenous (IV) abatacept","genericName":"Intravenous (IV) abatacept","slug":"intravenous-iv-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Open-label Abatacept","genericName":"Open-label Abatacept","slug":"open-label-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Orencia","genericName":"Orencia","slug":"orencia","indication":"Juvenile idiopathic arthritis","status":"marketed"},{"name":"PLA + MTX switched to ABA+ MTX, DB","genericName":"PLA + MTX switched to ABA+ MTX, DB","slug":"pla-mtx-switched-to-aba-mtx-db","indication":"Rheumatoid arthritis (as part of combination therapy with MTX)","status":"phase_3"},{"name":"Placebo (PLA) + MTX, DB","genericName":"Placebo (PLA) + MTX, DB","slug":"placebo-pla-mtx-db","indication":"Rheumatoid arthritis (as part of control arm in Phase 3 trial)","status":"phase_3"},{"name":"Placebo matching Ipilimumab","genericName":"Placebo matching Ipilimumab","slug":"placebo-matching-ipilimumab","indication":"Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens","status":"phase_3"},{"name":"Placebo matching with Abatacept","genericName":"Placebo matching with Abatacept","slug":"placebo-matching-with-abatacept","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Reyataz","genericName":"ATAZANAVIR","slug":"atazanavir","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Subcutaneous (SC) abatacept","genericName":"Subcutaneous (SC) abatacept","slug":"subcutaneous-sc-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Sustiva","genericName":"Sustiva","slug":"sustiva","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Sustiva","genericName":"EFAVIRENZ","slug":"efavirenz","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Videx","genericName":"DIDANOSINE","slug":"didanosine","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"abatacept (ABA)","genericName":"abatacept (ABA)","slug":"abatacept-aba","indication":"Rheumatoid arthritis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":427000000,"percentOfTotal":1,"drugCount":53,"colorKey":"neuroscience","drugs":[{"name":"Abecma","genericName":"idecabtagene vicleucel","slug":"idecabtagene-vicleucel","indication":"Other","status":"marketed","revenue":427000000},{"name":"BMS-986012","genericName":"BMS-986012","slug":"bms-986012","indication":"Other","status":"phase_2"},{"name":"BMS-986016","genericName":"BMS-986016","slug":"bms-986016","indication":"Other","status":"phase_2"},{"name":"BMS-986408","genericName":"BMS-986408","slug":"bms-986408","indication":"Other","status":"phase_1"},{"name":"KarX-EC","genericName":"KarX-EC","slug":"karx-ec","indication":"Other","status":"phase_3"},{"name":"Veronate","genericName":"Veronate","slug":"veronate","indication":"Other","status":"phase_1"},{"name":"Activated Charcoal with Sorbitol","genericName":"Activated Charcoal with Sorbitol","slug":"activated-charcoal-with-sorbitol","indication":"Management of acute poisoning","status":"phase_1"},{"name":"Active Pharmaceutical Ingredient","genericName":"Active Pharmaceutical Ingredient","slug":"active-pharmaceutical-ingredient","indication":"Other","status":"phase_1"},{"name":"Advanced therapy","genericName":"Advanced therapy","slug":"advanced-therapy","indication":"Other","status":"marketed"},{"name":"BMS-562086","genericName":"BMS-562086","slug":"bms-562086","indication":"Other","status":"phase_2"},{"name":"BMS-914392","genericName":"BMS-914392","slug":"bms-914392","indication":"Other","status":"phase_2"},{"name":"BMS-936558-01","genericName":"BMS-936558-01","slug":"bms-936558-01","indication":"Other","status":"phase_1"},{"name":"BMS-986142 200mg","genericName":"BMS-986142 200mg","slug":"bms-986142-200mg","indication":"Other","status":"phase_1"},{"name":"BMS-986166","genericName":"BMS-986166","slug":"bms-986166","indication":"Other","status":"phase_2"},{"name":"BMS-986207","genericName":"BMS-986207","slug":"bms-986207","indication":"Other","status":"phase_2"},{"name":"BMS-986213","genericName":"BMS-986213","slug":"bms-986213","indication":"Other","status":"phase_2"},{"name":"BMS-986259","genericName":"BMS-986259","slug":"bms-986259","indication":"Other","status":"phase_2"},{"name":"BMS-986322","genericName":"BMS-986322","slug":"bms-986322","indication":"Other","status":"phase_2"},{"name":"BMS-986340","genericName":"BMS-986340","slug":"bms-986340","indication":"Other","status":"phase_2"},{"name":"BMS-986435","genericName":"BMS-986435","slug":"bms-986435","indication":"Other","status":"phase_2"},{"name":"BMS-986446","genericName":"BMS-986446","slug":"bms-986446","indication":"Other","status":"phase_2"},{"name":"BMS-986458","genericName":"BMS-986458","slug":"bms-986458","indication":"Other","status":"phase_1"},{"name":"Belatacept LI (less intensive)","genericName":"Belatacept LI (less intensive)","slug":"belatacept-li-less-intensive","indication":"Prevention of organ rejection in kidney transplant recipients","status":"phase_3"},{"name":"Belatacept MI (more intensive)","genericName":"Belatacept MI (more intensive)","slug":"belatacept-mi-more-intensive","indication":"Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen)","status":"phase_3"},{"name":"Brivanab","genericName":"Brivanab","slug":"brivanab","indication":"Other","status":"phase_1"},{"name":"CXL-1427","genericName":"CXL-1427","slug":"cxl-1427","indication":"Other","status":"phase_2"},{"name":"Cocktail","genericName":"Cocktail","slug":"cocktail","indication":"Other","status":"marketed"},{"name":"Delalutin","genericName":"HYDROXYPROGESTERONE CAPROATE","slug":"hydroxyprogesterone-caproate","indication":"Prevention of Premature Labor","status":"marketed"},{"name":"Dextrotubocurarine Chloride","genericName":"TUBOCURARINE","slug":"tubocurarine","indication":"Muscle relaxation, function","status":"marketed"},{"name":"Dilitazem","genericName":"Dilitazem","slug":"dilitazem","indication":"Other","status":"phase_1"},{"name":"Enteric Coated Mycophenolate Sodium","genericName":"Enteric Coated Mycophenolate Sodium","slug":"enteric-coated-mycophenolate-sodium","indication":"Other","status":"marketed"},{"name":"Epivir","genericName":"Epivir","slug":"epivir","indication":"Other","status":"marketed"},{"name":"Etacillin","genericName":"HETACILLIN","slug":"hetacillin","indication":"Other","status":"marketed"},{"name":"Famotidine (FAM)","genericName":"Famotidine (FAM)","slug":"famotidine-fam","indication":"Duodenal ulcer","status":"marketed"},{"name":"IDO1 Inhibitor","genericName":"IDO1 Inhibitor","slug":"ido1-inhibitor","indication":"Other","status":"phase_1"},{"name":"Iza-bren","genericName":"Iza-bren","slug":"iza-bren","indication":"Other","status":"phase_2"},{"name":"Kinevac®","genericName":"Kinevac®","slug":"kinevac","indication":"Other","status":"marketed"},{"name":"Nulojix","genericName":"Nulojix","slug":"nulojix","indication":"Renal transplant rejection","status":"marketed"},{"name":"Nulojix","genericName":"BELATACEPT","slug":"belatacept","indication":"Renal transplant rejection","status":"marketed"},{"name":"OPDIVO QVANTIG","genericName":"HYALURONIDASE-NVHY","slug":"hyaluronidase-nvhy","indication":"Other","status":"marketed"},{"name":"Panolosetron","genericName":"Panolosetron","slug":"panolosetron","indication":"Other","status":"phase_1"},{"name":"Pemexetred","genericName":"Pemexetred","slug":"pemexetred","indication":"Other","status":"discontinued"},{"name":"Placebo for Nivolumab","genericName":"Placebo for Nivolumab","slug":"placebo-for-nivolumab","indication":"Control arm in Phase 3 clinical trials of Nivolumab","status":"phase_3"},{"name":"Placebo for apixaban","genericName":"Placebo for apixaban","slug":"placebo-for-apixaban","indication":"Control arm in apixaban clinical trials (specific indication depends on parent trial)","status":"phase_3"},{"name":"Placebo matching Dacarbazine","genericName":"Placebo matching Dacarbazine","slug":"placebo-matching-dacarbazine","indication":"Control arm in Phase 3 trial (specific indication unknown without trial protocol)","status":"phase_3"},{"name":"Placebo matching with Metformin XR","genericName":"Placebo matching with Metformin XR","slug":"placebo-matching-with-metformin-xr","indication":"Clinical trial control for studies evaluating Metformin XR efficacy and safety","status":"marketed"},{"name":"Prenisolone","genericName":"Prenisolone","slug":"prenisolone","indication":"Other","status":"phase_1"},{"name":"Regorafinib","genericName":"Regorafinib","slug":"regorafinib","indication":"Other","status":"phase_2"},{"name":"Ribasphere","genericName":"Ribasphere","slug":"ribasphere","indication":"Other","status":"phase_2"},{"name":"Treatment A: Mavacamten intact oral capsule","genericName":"Treatment A: Mavacamten intact oral capsule","slug":"treatment-a-mavacamten-intact-oral-capsule","indication":"Other","status":"phase_1"},{"name":"efavirenz, stavudine extended release, lamivudine","genericName":"efavirenz, stavudine extended release, lamivudine","slug":"efavirenz-stavudine-extended-release-lamivudine","indication":"Other","status":"marketed"},{"name":"or Glyburide alone.","genericName":"or Glyburide alone.","slug":"or-glyburide-alone","indication":"Other","status":"marketed"},{"name":"panHer","genericName":"panHer","slug":"panher","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":40,"colorKey":"respiratory","drugs":[{"name":"Kanacin","genericName":"KANAMYCIN","slug":"kanamycin","indication":"Bacterial pneumonia","status":"marketed"},{"name":"Arikayce Kit","genericName":"AMIKACIN","slug":"amikacin","indication":"Bacterial infection due to Klebsiella pneumoniae","status":"marketed"},{"name":"Azactam","genericName":"AZTREONAM","slug":"aztreonam","indication":"Aerobic Gram-Negative Bacteremia","status":"marketed"},{"name":"Baraclude","genericName":"ENTECAVIR","slug":"entecavir","indication":"Chronic type B viral hepatitis","status":"marketed"},{"name":"Daklinza","genericName":"DACLATASVIR","slug":"daclatasvir","indication":"Chronic hepatitis C","status":"marketed"},{"name":"LPV","genericName":"LPV","slug":"lpv","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Tenofovir/Emtricitabine","genericName":"Tenofovir/Emtricitabine","slug":"tenofovir-emtricitabine","indication":"HIV-1 infection (treatment)","status":"marketed"},{"name":"Unasyn","genericName":"AMPICILLIN","slug":"ampicillin","indication":"Acute bacterial epiglottitis","status":"marketed"},{"name":"Videx EC","genericName":"Videx EC","slug":"videx-ec","indication":"HIV-1 infection (in combination antiretroviral therapy)","status":"phase_3"},{"name":"stavudine extended-release, lamivudine, efavirenz","genericName":"stavudine extended-release, lamivudine, efavirenz","slug":"stavudine-extended-release-lamivudine-efavirenz","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"},{"name":"Adefovir (ADV)","genericName":"Adefovir (ADV)","slug":"adefovir-adv","indication":"Chronic hepatitis B infection","status":"phase_3"},{"name":"Adefovir/Entecavir","genericName":"Adefovir/Entecavir","slug":"adefovir-entecavir","indication":"Chronic hepatitis B infection","status":"marketed"},{"name":"Asunaprevir (ASV)","genericName":"Asunaprevir (ASV)","slug":"asunaprevir-asv","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1b","status":"phase_3"},{"name":"Atazanavir (Week 24 switch)","genericName":"Atazanavir (Week 24 switch)","slug":"atazanavir-week-24-switch","indication":"HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Atazanavir (immediate switch)","genericName":"Atazanavir (immediate switch)","slug":"atazanavir-immediate-switch","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults","status":"phase_3"},{"name":"Atazanavir + 2 NRTIs","genericName":"Atazanavir + 2 NRTIs","slug":"atazanavir-2-nrtis","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Atazanavir + Ritonavir + 2 NRTIs","genericName":"Atazanavir + Ritonavir + 2 NRTIs","slug":"atazanavir-ritonavir-2-nrtis","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Atazanavir + ritonavir + tenofovir + nucleoside","genericName":"Atazanavir + ritonavir + tenofovir + nucleoside","slug":"atazanavir-ritonavir-tenofovir-nucleoside","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Atazanavir + saquinavir + tenofovir + nucleoside","genericName":"Atazanavir + saquinavir + tenofovir + nucleoside","slug":"atazanavir-saquinavir-tenofovir-nucleoside","indication":"HIV-1 infection","status":"phase_3"},{"name":"Atazanavir capsules","genericName":"Atazanavir capsules","slug":"atazanavir-capsules","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","genericName":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","slug":"atazanavir-ritonavir-stavidine-lamivudine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Atazanavir/ Stavidine / Lamivudine","genericName":"Atazanavir/ Stavidine / Lamivudine","slug":"atazanavir-stavidine-lamivudine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Atazanavir/Ritonavir + Famotidine","genericName":"Atazanavir/Ritonavir + Famotidine","slug":"atazanavir-ritonavir-famotidine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Atazanvir/ritonavir + efavirenz","genericName":"Atazanvir/ritonavir + efavirenz","slug":"atazanvir-ritonavir-efavirenz","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"BECLABUVIR","genericName":"BECLABUVIR","slug":"beclabuvir","indication":"Chronic hepatitis C","status":"marketed"},{"name":"BMS-650032 (Asunaprevir)","genericName":"BMS-650032 (Asunaprevir)","slug":"bms-650032-asunaprevir","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1b","status":"phase_3"},{"name":"BMS-790052 (Daclatasvir)","genericName":"BMS-790052 (Daclatasvir)","slug":"bms-790052-daclatasvir","indication":"Chronic hepatitis C virus infection (genotype 1-6)","status":"phase_3"},{"name":"Baraclude","genericName":"Baraclude","slug":"baraclude","indication":"Chronic type B viral hepatitis","status":"marketed"},{"name":"Cefaprin","genericName":"cefapirin","slug":"cefapirin","indication":"Bacterial endocarditis","status":"marketed"},{"name":"Cefradex","genericName":"cefradine","slug":"cefradine","indication":"Acute otitis media","status":"marketed"},{"name":"DCV","genericName":"DCV","slug":"dcv","indication":"Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals","status":"phase_3"},{"name":"DCV 3DAA","genericName":"DCV 3DAA","slug":"dcv-3daa","indication":"Chronic hepatitis C virus infection (genotype 1-6)","status":"phase_3"},{"name":"DCV/ASV/BMS-791325","genericName":"DCV/ASV/BMS-791325","slug":"dcv-asv-bms-791325","indication":"Chronic hepatitis C virus infection (genotype 1-6)","status":"phase_3"},{"name":"Lamivudine/Zidovudine","genericName":"Lamivudine/Zidovudine","slug":"lamivudine-zidovudine","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"marketed"},{"name":"Lopinavir/ritonavir + tenofovir + nucleoside","genericName":"Lopinavir/ritonavir + tenofovir + nucleoside","slug":"lopinavir-ritonavir-tenofovir-nucleoside","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Metacillin","genericName":"meticillin","slug":"meticillin","indication":"Bacterial septicemia","status":"marketed"},{"name":"Placebo matching BMS-790052","genericName":"Placebo matching BMS-790052","slug":"placebo-matching-bms-790052","indication":"Chronic hepatitis C virus infection (genotype 1)","status":"phase_3"},{"name":"Placebo matching Ribavirin","genericName":"Placebo matching Ribavirin","slug":"placebo-matching-ribavirin","indication":"Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design)","status":"phase_3"},{"name":"Ritonavir (heat-stable)","genericName":"Ritonavir (heat-stable)","slug":"ritonavir-heat-stable","indication":"HIV-1 infection (in combination with other antiretroviral agents)","status":"marketed"},{"name":"stavudine, efavirenz, lamivudine","genericName":"stavudine, efavirenz, lamivudine","slug":"stavudine-efavirenz-lamivudine","indication":"HIV-1 infection","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"rare","drugs":[{"name":"Xanomeline Enteric Capsule","genericName":"Xanomeline Enteric Capsule","slug":"xanomeline-enteric-capsule","indication":"Alzheimer's disease","status":"phase_3"},{"name":"BMS-708163","genericName":"BMS-708163","slug":"bms-708163","indication":"Alzheimer's disease","status":"phase_2"},{"name":"Moditen Enanthate","genericName":"FLUPHENAZINE ENANTHATE","slug":"fluphenazine-enanthate","indication":"Psychotic disorder","status":"marketed"},{"name":"Prolixin Decanoate","genericName":"FLUPHENAZINE DECANOATE","slug":"fluphenazine-decanoate","indication":"Psychotic disorder","status":"marketed"},{"name":"Serzone","genericName":"NEFAZODONE","slug":"nefazodone","indication":"Major depressive disorder","status":"marketed"},{"name":"Antidepressant + Aripiprazole","genericName":"Antidepressant + Aripiprazole","slug":"antidepressant-aripiprazole","indication":"Major depressive disorder, treatment-resistant or inadequate response to antidepressant monotherapy","status":"phase_3"},{"name":"Aurexis®","genericName":"Aurexis®","slug":"aurexis","indication":"Major depressive disorder","status":"phase_2"},{"name":"Extended Phenytoin Sodium","genericName":"Extended Phenytoin Sodium","slug":"extended-phenytoin-sodium","indication":"Generalized tonic-clonic seizures","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Acetadote","genericName":"Acetylcysteine","slug":"acetylcysteine","indication":"Amyloidosis","status":"marketed"},{"name":"Corticosteroid: Triamcinolone","genericName":"Corticosteroid: Triamcinolone","slug":"corticosteroid-triamcinolone","indication":"Nephrotic syndrome","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"ophthalmology","drugs":[{"name":"Placebo matching with Metformin IR","genericName":"Placebo matching with Metformin IR","slug":"placebo-matching-with-metformin-ir","indication":"Used as control arm in clinical trials for type 2 diabetes or related metabolic disorders","status":"marketed"},{"name":"or Metformin HCl alone","genericName":"or Metformin HCl alone","slug":"or-metformin-hcl-alone","indication":"Type 2 diabetes mellitus","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Ortho Tri-Cyclen LO","genericName":"Ortho Tri-Cyclen LO","slug":"ortho-tri-cyclen-lo","indication":"Contraception (pregnancy prevention)","status":"marketed"}]}],"pipeline":[{"name":"Eliquis","genericName":"apixaban","slug":"apixaban","phase":"marketed","mechanism":"Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development.","indications":["Arterial embolus and thrombosis","Myocardial Reinfarction Prevention"],"catalyst":""},{"name":"Opdivo","genericName":"nivolumab","slug":"nivolumab","phase":"marketed","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.","indications":["Advanced melanoma with tumour cell PD-L1 expression below 1%","Classical Hodgkin lymphoma","Head and neck cancer","Malignant tumor of esophagus","Malignant tumor of stomach"],"catalyst":""},{"name":"Revlimid","genericName":"lenalidomide","slug":"lenalidomide","phase":"marketed","mechanism":"Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation.","indications":["Follicular lymphoma","Mantle cell lymphoma","Marginal zone lymphoma","Multiple myeloma","Myelodysplastic syndrome"],"catalyst":""},{"name":"Orencia","genericName":"abatacept","slug":"abatacept","phase":"marketed","mechanism":"Abatacept inhibits T-cell activation by binding CD80/CD86, blocking CD28 costimulatory interaction.","indications":["Juvenile idiopathic arthritis","Rheumatoid arthritis"],"catalyst":""},{"name":"Yervoy","genericName":"ipilimumab","slug":"ipilimumab","phase":"discontinued","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells.","indications":["High grade squamous intraepithelial neoplasia of esophagus","Metastatic malignant melanoma","Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","Microsatellite instability-high colorectal cancer","Renal cell carcinoma"],"catalyst":""},{"name":"Pomalyst","genericName":"pomalidomide","slug":"pomalidomide","phase":"marketed","mechanism":"Pomalyst works by binding to the cereblon protein, which disrupts the function of certain genes involved in cancer cell growth.","indications":["Multiple myeloma"],"catalyst":""},{"name":"Zeposia","genericName":"OZANIMOD","slug":"ozanimod","phase":"marketed","mechanism":"Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression.","indications":["Multiple sclerosis","Relapsing remitting multiple sclerosis","Ulcerative colitis"],"catalyst":""},{"name":"Camzyos","genericName":"MAVACAMTEN","slug":"mavacamten","phase":"marketed","mechanism":"Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM.","indications":["Obstructive hypertrophic cardiomyopathy (HCM)"],"catalyst":""},{"name":"Abecma","genericName":"idecabtagene vicleucel","slug":"idecabtagene-vicleucel","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Sotyktu","genericName":"DEUCRAVACITINIB","slug":"deucravacitinib","phase":"marketed","mechanism":"Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis.","indications":["Moderate-to-severe plaque psoriasis","Active psoriatic arthritis"],"catalyst":""},{"name":"Krazati","genericName":"ADAGRASIB","slug":"adagrasib","phase":"marketed","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth.","indications":["KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Acetadote","genericName":"Acetylcysteine","slug":"acetylcysteine","phase":"marketed","mechanism":"Acetylcysteine reduces liver injury from acetaminophen overdose by maintaining glutathione levels or providing alternate conjugation substrate.","indications":["Amyloidosis","Atelectasis due to Mucous Obstruction","Bronchiectasis","Bronchitis","Contrast Media-Induced Nephrotoxicity Prevention"],"catalyst":""},{"name":"Huluc63","genericName":"elotuzumab","slug":"elotuzumab","phase":"marketed","mechanism":"Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells.","indications":["Multiple myeloma","Relapse multiple myeloma"],"catalyst":""},{"name":"Vidaza","genericName":"azacitidine","slug":"azacitidine","phase":"marketed","mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells.","indications":["Refractory Anemia (RA)","Refractory Anemia with Ringed Sideroblasts (RARS)","Refractory Anemia with Excess Blasts (RAEB)","Refractory Anemia with Excess Blasts in Transformation (RAEB-T)","Chronic Myelomonocytic Leukemia (CMMoL)"],"catalyst":""},{"name":"Vepesid","genericName":"etoposide","slug":"etoposide","phase":"marketed","mechanism":"DNA topoisomerase 2-alpha","indications":["Malignant tumor of testis","Small cell carcinoma of lung","Treatment prior to tumor-specific T-cell infusion therapy"],"catalyst":""},{"name":"BMS-986012","genericName":"BMS-986012","slug":"bms-986012","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Kanacin","genericName":"KANAMYCIN","slug":"kanamycin","phase":"marketed","mechanism":"Gap junction beta-2 protein","indications":["Bacterial pneumonia","Bacterial septicemia","Burn Wound Infections","Cholangitis","Infection of bone"],"catalyst":""},{"name":"Ramipril + Irbesartan","genericName":"Ramipril + Irbesartan","slug":"ramipril-irbesartan","phase":"marketed","mechanism":"This combination lowers blood pressure by blocking angiotensin II through two complementary pathways: ACE inhibition and angiotensin II receptor antagonism.","indications":["Hypertension in patients not adequately controlled on monotherapy"],"catalyst":""},{"name":"Xanomeline Enteric Capsule","genericName":"Xanomeline Enteric Capsule","slug":"xanomeline-enteric-capsule","phase":"phase_3","mechanism":"Xanomeline is a muscarinic receptor agonist that targets the M1 and M4 subtypes.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Arikayce Kit","genericName":"AMIKACIN","slug":"amikacin","phase":"marketed","mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.","indications":["Bacterial infection due to Klebsiella pneumoniae","Bacterial infection due to Serratia","Bacterial meningitis","Bacterial meningitis due to Gram-negative bacteria","Bacterial pneumonia"],"catalyst":""},{"name":"Azactam","genericName":"AZTREONAM","slug":"aztreonam","phase":"marketed","mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent.","indications":["Aerobic Gram-Negative Bacteremia","Bacterial Exacerbation of Acute Bronchitis","Bacterial infection due to Klebsiella pneumoniae","Bacterial infection due to Serratia","Bacterial peritonitis"],"catalyst":""},{"name":"BMS-708163","genericName":"BMS-708163","slug":"bms-708163","phase":"phase_2","mechanism":"BMS-708163 inhibits the activity of beta-secretase (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are associated with Alzheimer's disease.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"BMS-986016","genericName":"BMS-986016","slug":"bms-986016","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986165","genericName":"BMS-986165","slug":"bms-986165","phase":"marketed","mechanism":"BMS-986165 is a selective inhibitor of the interleukin-12 and interleukin-23 (IL-12/IL-23) p40 subunit that reduces inflammatory signaling in immune-mediated diseases.","indications":["Psoriasis","Psoriatic arthritis","Crohn's disease"],"catalyst":""},{"name":"BMS-986205","genericName":"BMS-986205","slug":"bms-986205","phase":"phase_3","mechanism":"BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.","indications":["Acute coronary syndrome","Chronic kidney disease"],"catalyst":""},{"name":"BMS-986231","genericName":"BMS-986231","slug":"bms-986231","phase":"phase_2","mechanism":"BMS-986231 is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"BMS-986374","genericName":"BMS-986374","slug":"bms-986374","phase":"marketed","mechanism":"BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins.","indications":["Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion","Other solid tumors with MTAP loss or PRMT5 dependency"],"catalyst":""},{"name":"BMS-986408","genericName":"BMS-986408","slug":"bms-986408","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Baraclude","genericName":"ENTECAVIR","slug":"entecavir","phase":"marketed","mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus.","indications":["Chronic type B viral hepatitis","Lamivudine-Refractory Chronic Hepatitis B"],"catalyst":""},{"name":"Blenoxane","genericName":"BLEOMYCIN","slug":"bleomycin","phase":"marketed","mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death.","indications":["Diffuse non-Hodgkin's lymphoma, large cell","Follicular non-Hodgkin's lymphoma","Hodgkin's disease","International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma","Malignant tumor of cervix"],"catalyst":""},{"name":"Daklinza","genericName":"DACLATASVIR","slug":"daclatasvir","phase":"marketed","mechanism":"Potassium voltage-gated channel subfamily H member 2","indications":["Chronic hepatitis C"],"catalyst":""},{"name":"Immunotherapy monotherapy","genericName":"Immunotherapy monotherapy","slug":"immunotherapy-monotherapy","phase":"phase_2","mechanism":"Immune checkpoint inhibitor","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"Inrebic","genericName":"FEDRATINIB","slug":"fedratinib","phase":"marketed","mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells.","indications":["Myelofibrosis","Post-essential thrombocythaemia myelofibrosis","Post-polycythaemia vera myelofibrosis","Primary myelofibrosis"],"catalyst":""},{"name":"KarX-EC","genericName":"KarX-EC","slug":"karx-ec","phase":"phase_3","mechanism":"KarX-EC is an extended-release formulation designed to improve the pharmacokinetic profile and therapeutic delivery of its active component.","indications":[],"catalyst":""},{"name":"LPV","genericName":"LPV","slug":"lpv","phase":"phase_3","mechanism":"LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","COVID-19 (investigational use in phase 3)"],"catalyst":""},{"name":"Moditen Enanthate","genericName":"FLUPHENAZINE ENANTHATE","slug":"fluphenazine-enanthate","phase":"marketed","mechanism":"D(3) dopamine receptor","indications":["Psychotic disorder","Schizophrenia"],"catalyst":""},{"name":"Prolixin Decanoate","genericName":"FLUPHENAZINE DECANOATE","slug":"fluphenazine-decanoate","phase":"marketed","mechanism":"D(2) dopamine receptor","indications":["Psychotic disorder","Schizophrenia"],"catalyst":""},{"name":"Serzone","genericName":"NEFAZODONE","slug":"nefazodone","phase":"marketed","mechanism":"Sodium-dependent serotonin transporter","indications":["Major depressive disorder"],"catalyst":""},{"name":"Tenofovir/Emtricitabine","genericName":"Tenofovir/Emtricitabine","slug":"tenofovir-emtricitabine","phase":"marketed","mechanism":"Tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","indications":["HIV-1 infection (treatment)","HIV-1 pre-exposure prophylaxis (PrEP)"],"catalyst":""},{"name":"Unasyn","genericName":"AMPICILLIN","slug":"ampicillin","phase":"marketed","mechanism":"Transient receptor potential cation channel subfamily M member 4","indications":["Acute bacterial epiglottitis","Acute bacterial sinusitis","Acute epiglottitis","Acute exacerbation of chronic bronchitis","Acute gonococcal cervicitis"],"catalyst":""},{"name":"Veronate","genericName":"Veronate","slug":"veronate","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Videx EC","genericName":"Videx EC","slug":"videx-ec","phase":"phase_3","mechanism":"Videx EC is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.","indications":["HIV-1 infection (in combination antiretroviral therapy)"],"catalyst":""},{"name":"stavudine extended-release, lamivudine, efavirenz","genericName":"stavudine extended-release, lamivudine, efavirenz","slug":"stavudine-extended-release-lamivudine-efavirenz","phase":"phase_3","mechanism":"Stavudine extended-release, lamivudine, and efavirenz work together to inhibit viral replication by targeting the HIV reverse transcriptase enzyme and the HIV non-nucleoside reverse transcriptase inhibitor binding site.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of HIV-1 infection in adults and children"],"catalyst":""},{"name":"ABA, open-label (OL)","genericName":"ABA, open-label (OL)","slug":"aba-open-label-ol","phase":"phase_3","mechanism":"Nivolumab is an immune checkpoint inhibitor that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.","indications":["Metastatic melanoma","Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Abatacept subcutaneous","genericName":"Abatacept subcutaneous","slug":"abatacept-subcutaneous","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Activated Charcoal with Sorbitol","genericName":"Activated Charcoal with Sorbitol","slug":"activated-charcoal-with-sorbitol","phase":"phase_1","mechanism":"Activated charcoal adsorbs toxins and excess gases in the gastrointestinal tract, while sorbitol acts as a laxative to facilitate their removal.","indications":["Management of acute poisoning","Relief of bloating and gas"],"catalyst":""},{"name":"Active Pharmaceutical Ingredient","genericName":"Active Pharmaceutical Ingredient","slug":"active-pharmaceutical-ingredient","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adefovir (ADV)","genericName":"Adefovir (ADV)","slug":"adefovir-adv","phase":"phase_3","mechanism":"Adefovir is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus.","indications":["Chronic hepatitis B infection","HBV with lamivudine resistance"],"catalyst":""},{"name":"Adefovir/Entecavir","genericName":"Adefovir/Entecavir","slug":"adefovir-entecavir","phase":"marketed","mechanism":"Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase.","indications":["Chronic hepatitis B infection","Lamivudine-resistant hepatitis B (adefovir)"],"catalyst":""},{"name":"Advanced therapy","genericName":"Advanced therapy","slug":"advanced-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anti-IL8","genericName":"Anti-IL8","slug":"anti-il8","phase":"phase_2","mechanism":"Anti-IL8 binds to interleukin-8 (IL-8), a chemokine involved in inflammation, to reduce its activity.","indications":["Moderate to severe chronic plaque psoriasis","Rheumatoid arthritis"],"catalyst":""},{"name":"Anti-IP-10 Antibody","genericName":"Anti-IP-10 Antibody","slug":"anti-ip-10-antibody","phase":"phase_2","mechanism":"Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation.","indications":["Psoriasis"],"catalyst":""},{"name":"Antidepressant + Aripiprazole","genericName":"Antidepressant + Aripiprazole","slug":"antidepressant-aripiprazole","phase":"phase_3","mechanism":"This combination enhances serotonergic and noradrenergic neurotransmission via antidepressant action while aripiprazole provides dopaminergic stabilization and augmentation of antidepressant efficacy.","indications":["Major depressive disorder, treatment-resistant or inadequate response to antidepressant monotherapy"],"catalyst":""},{"name":"Any biologic treatment for psoriasis","genericName":"Any biologic treatment for psoriasis","slug":"any-biologic-treatment-for-psoriasis","phase":"phase_2","mechanism":"Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body.","indications":["Moderate to severe plaque psoriasis","Moderate to severe scalp psoriasis"],"catalyst":""},{"name":"Approved Hypertrophic Cardiomyopathy drug treatments","genericName":"Approved Hypertrophic Cardiomyopathy drug treatments","slug":"approved-hypertrophic-cardiomyopathy-drug-treatments","phase":"phase_2","mechanism":"Calcium channel blocker","indications":["Hypertrophic cardiomyopathy"],"catalyst":""},{"name":"Asunaprevir (ASV)","genericName":"Asunaprevir (ASV)","slug":"asunaprevir-asv","phase":"phase_3","mechanism":"Asunaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1b"],"catalyst":""},{"name":"Atazanavir (Week 24 switch)","genericName":"Atazanavir (Week 24 switch)","slug":"atazanavir-week-24-switch","phase":"phase_3","mechanism":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.","indications":["HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Atazanavir (immediate switch)","genericName":"Atazanavir (immediate switch)","slug":"atazanavir-immediate-switch","phase":"phase_3","mechanism":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"Atazanavir + 2 NRTIs","genericName":"Atazanavir + 2 NRTIs","slug":"atazanavir-2-nrtis","phase":"marketed","mechanism":"Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection as part of combination antiretroviral therapy"],"catalyst":""},{"name":"Atazanavir + Ritonavir + 2 NRTIs","genericName":"Atazanavir + Ritonavir + 2 NRTIs","slug":"atazanavir-ritonavir-2-nrtis","phase":"marketed","mechanism":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and the two NRTIs inhibit reverse transcriptase to block HIV DNA synthesis.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in combination with other antiretroviral agents"],"catalyst":""},{"name":"Atazanavir + ritonavir + tenofovir + nucleoside","genericName":"Atazanavir + ritonavir + tenofovir + nucleoside","slug":"atazanavir-ritonavir-tenofovir-nucleoside","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication in HIV-infected patients.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Atazanavir + saquinavir + tenofovir + nucleoside","genericName":"Atazanavir + saquinavir + tenofovir + nucleoside","slug":"atazanavir-saquinavir-tenofovir-nucleoside","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection"],"catalyst":""},{"name":"Atazanavir capsules","genericName":"Atazanavir capsules","slug":"atazanavir-capsules","phase":"phase_3","mechanism":"Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","genericName":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","slug":"atazanavir-ritonavir-stavidine-lamivudine","phase":"marketed","mechanism":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Atazanavir/ Stavidine / Lamivudine","genericName":"Atazanavir/ Stavidine / Lamivudine","slug":"atazanavir-stavidine-lamivudine","phase":"marketed","mechanism":"This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Atazanavir/Ritonavir + Famotidine","genericName":"Atazanavir/Ritonavir + Famotidine","slug":"atazanavir-ritonavir-famotidine","phase":"marketed","mechanism":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and famotidine reduces gastric acid to improve atazanavir absorption.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults"],"catalyst":""},{"name":"Atazanvir/ritonavir + efavirenz","genericName":"Atazanvir/ritonavir + efavirenz","slug":"atazanvir-ritonavir-efavirenz","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Aurexis®","genericName":"Aurexis®","slug":"aurexis","phase":"phase_2","mechanism":"Selective serotonin reuptake inhibitor","indications":["Major depressive disorder"],"catalyst":""},{"name":"BECLABUVIR","genericName":"BECLABUVIR","slug":"beclabuvir","phase":"marketed","mechanism":"Potassium voltage-gated channel subfamily H member 2","indications":["Chronic hepatitis C"],"catalyst":""},{"name":"BET Inhibitor","genericName":"BET Inhibitor","slug":"bet-inhibitor","phase":"phase_2","mechanism":"BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins","indications":["T-cell lymphoma","Multiple myeloma"],"catalyst":""},{"name":"BMS-562086","genericName":"BMS-562086","slug":"bms-562086","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-650032","genericName":"BMS-650032","slug":"bms-650032","phase":"phase_2","mechanism":"BMS-650032 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune response.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"BMS-650032 (Asunaprevir)","genericName":"BMS-650032 (Asunaprevir)","slug":"bms-650032-asunaprevir","phase":"phase_3","mechanism":"Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1b"],"catalyst":""},{"name":"BMS-790052","genericName":"BMS-790052","slug":"bms-790052","phase":"phase_2","mechanism":"BMS-790052 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck cancer"],"catalyst":""},{"name":"BMS-790052 (Daclatasvir)","genericName":"BMS-790052 (Daclatasvir)","slug":"bms-790052-daclatasvir","phase":"phase_3","mechanism":"Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread.","indications":["Chronic hepatitis C virus infection (genotype 1-6)","Hepatitis C in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"BMS-914392","genericName":"BMS-914392","slug":"bms-914392","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-936558 (Nivolumab)","genericName":"BMS-936558 (Nivolumab)","slug":"bms-936558-nivolumab","phase":"phase_3","mechanism":"Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Advanced non-small cell lung cancer","Renal cell carcinoma","Classical Hodgkin lymphoma","Squamous cell carcinoma of the head and neck"],"catalyst":""},{"name":"BMS-936558-01","genericName":"BMS-936558-01","slug":"bms-936558-01","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-954561","genericName":"BMS-954561","slug":"bms-954561","phase":"phase_2","mechanism":"BMS-954561 is a small molecule that targets the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"BMS-986142 200mg","genericName":"BMS-986142 200mg","slug":"bms-986142-200mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986165 Dose A","genericName":"BMS-986165 Dose A","slug":"bms-986165-dose-a","phase":"phase_2","mechanism":"BMS-986165 Dose A is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer, PD-L1 positive","Melanoma"],"catalyst":""},{"name":"BMS-986165 Dose B","genericName":"BMS-986165 Dose B","slug":"bms-986165-dose-b","phase":"phase_2","mechanism":"BMS-986165 is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive","Melanoma"],"catalyst":""},{"name":"BMS-986166","genericName":"BMS-986166","slug":"bms-986166","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986177","genericName":"BMS-986177","slug":"bms-986177","phase":"phase_2","mechanism":"BMS-986177 is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"BMS-986207","genericName":"BMS-986207","slug":"bms-986207","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986213","genericName":"BMS-986213","slug":"bms-986213","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BMS-986259","genericName":"BMS-986259","slug":"bms-986259","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986278","genericName":"BMS-986278","slug":"bms-986278","phase":"phase_3","mechanism":"BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.","indications":["Acute coronary syndrome","Chronic kidney disease"],"catalyst":""},{"name":"BMS-986322","genericName":"BMS-986322","slug":"bms-986322","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986340","genericName":"BMS-986340","slug":"bms-986340","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986435","genericName":"BMS-986435","slug":"bms-986435","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986446","genericName":"BMS-986446","slug":"bms-986446","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986458","genericName":"BMS-986458","slug":"bms-986458","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986504","genericName":"BMS-986504","slug":"bms-986504","phase":"phase_2","mechanism":"BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Baraclude","genericName":"Baraclude","slug":"baraclude","phase":"marketed","mechanism":"Capsid protein, Protein P, Protein P","indications":["Chronic type B viral hepatitis","Lamivudine-Refractory Chronic Hepatitis B"],"catalyst":""},{"name":"Belatacept LI (less intensive)","genericName":"Belatacept LI (less intensive)","slug":"belatacept-li-less-intensive","phase":"phase_3","mechanism":"Belatacept is a selective T-cell costimulation blocker that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells.","indications":["Prevention of organ rejection in kidney transplant recipients"],"catalyst":""},{"name":"Belatacept MI (more intensive)","genericName":"Belatacept MI (more intensive)","slug":"belatacept-mi-more-intensive","phase":"phase_3","mechanism":"Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation.","indications":["Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen)"],"catalyst":""},{"name":"Brivanab","genericName":"Brivanab","slug":"brivanab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CXL-1427","genericName":"CXL-1427","slug":"cxl-1427","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Carboplatin/Paraplatin","genericName":"Carboplatin/Paraplatin","slug":"carboplatin-paraplatin","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.","indications":["Ovarian cancer","Non-small cell lung cancer","Small cell lung cancer","Head and neck cancer","Breast cancer"],"catalyst":""},{"name":"Cefaprin","genericName":"cefapirin","slug":"cefapirin","phase":"marketed","mechanism":"Sigma non-opioid intracellular receptor 1","indications":["Bacterial endocarditis","Bacterial infection due to Klebsiella pneumoniae","Bacterial septicemia","Escherichia coli urinary tract infection","Haemophilus influenzae pneumonia"],"catalyst":""},{"name":"Cefradex","genericName":"cefradine","slug":"cefradine","phase":"marketed","mechanism":"Matrix metalloproteinase-9","indications":["Acute otitis media","Bacterial infection due to Klebsiella pneumoniae","Enterococcus Prostatitis","Enterococcus Urinary Tract Infection","Escherichia coli urinary tract infection"],"catalyst":""},{"name":"Cetuximab/Erbitux","genericName":"Cetuximab/Erbitux","slug":"cetuximab-erbitux","phase":"phase_3","mechanism":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.","indications":["Metastatic colorectal cancer (KRAS wild-type)","Head and neck squamous cell carcinoma","Non-small cell lung cancer (EGFR-expressing)"],"catalyst":""},{"name":"Cisplatin/Platinol","genericName":"Cisplatin/Platinol","slug":"cisplatin-platinol","phase":"phase_3","mechanism":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and triggering cancer cell death.","indications":["Metastatic testicular cancer","Metastatic ovarian cancer","Advanced bladder cancer","Head and neck cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Cocktail","genericName":"Cocktail","slug":"cocktail","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Corticosteroid: Meprednisone","genericName":"Corticosteroid: Meprednisone","slug":"corticosteroid-meprednisone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Treatment of various cancers"],"catalyst":""},{"name":"Corticosteroid: Methylprednisolone","genericName":"Corticosteroid: Methylprednisolone","slug":"corticosteroid-methylprednisolone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Multiple sclerosis","Rheumatoid arthritis","Asthma"],"catalyst":""},{"name":"Corticosteroid: Prednisone","genericName":"Corticosteroid: Prednisone","slug":"corticosteroid-prednisone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Rheumatoid arthritis","Asthma","Multiple sclerosis"],"catalyst":""},{"name":"Corticosteroid: Triamcinolone","genericName":"Corticosteroid: Triamcinolone","slug":"corticosteroid-triamcinolone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Nephrotic syndrome","Severe asthma","Severe allergies"],"catalyst":""},{"name":"DCV","genericName":"DCV","slug":"dcv","phase":"phase_3","mechanism":"DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals"],"catalyst":""},{"name":"DCV 3DAA","genericName":"DCV 3DAA","slug":"dcv-3daa","phase":"phase_3","mechanism":"DCV 3DAA is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus NS3/4A protease, NS5B polymerase, and NS5A protein to block viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1-6)"],"catalyst":""},{"name":"DCV/ASV/BMS-791325","genericName":"DCV/ASV/BMS-791325","slug":"dcv-asv-bms-791325","phase":"phase_3","mechanism":"This is a three-drug combination of direct-acting antivirals (DCV, ASV, and BMS-791325) that inhibit hepatitis C virus NS5A, NS3 protease, and NS5B polymerase respectively to block viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1-6)"],"catalyst":""},{"name":"Delalutin","genericName":"HYDROXYPROGESTERONE CAPROATE","slug":"hydroxyprogesterone-caproate","phase":"marketed","mechanism":"Corticosteroid-binding globulin","indications":["Prevention of Premature Labor"],"catalyst":""},{"name":"Dextrotubocurarine Chloride","genericName":"TUBOCURARINE","slug":"tubocurarine","phase":"marketed","mechanism":"Acetylcholine receptor","indications":["Muscle relaxation, function"],"catalyst":""},{"name":"Dilitazem","genericName":"Dilitazem","slug":"dilitazem","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Double-blind Abatacept","genericName":"Double-blind Abatacept","slug":"double-blind-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Enteric Coated Mycophenolate Sodium","genericName":"Enteric Coated Mycophenolate Sodium","slug":"enteric-coated-mycophenolate-sodium","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Epivir","genericName":"Epivir","slug":"epivir","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Etacillin","genericName":"HETACILLIN","slug":"hetacillin","phase":"marketed","mechanism":"Penicillin-binding protein","indications":[],"catalyst":""},{"name":"Extended Phenytoin Sodium","genericName":"Extended Phenytoin Sodium","slug":"extended-phenytoin-sodium","phase":"marketed","mechanism":"Extended-release phenytoin sodium blocks voltage-gated sodium channels in the brain to reduce neuronal excitability and prevent seizure propagation.","indications":["Generalized tonic-clonic seizures","Complex partial (temporal lobe) seizures","Simple partial seizures","Status epilepticus (parenteral formulation)"],"catalyst":""},{"name":"Famotidine (FAM)","genericName":"Famotidine (FAM)","slug":"famotidine-fam","phase":"marketed","mechanism":"Famotidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells in the stomach.","indications":["Duodenal ulcer","Gastric ulcer","Gastroesophageal reflux disease (GERD)","Zollinger-Ellison syndrome","Peptic ulcer disease prophylaxis"],"catalyst":""},{"name":"Fluorouracil/Adrucil","genericName":"Fluorouracil/Adrucil","slug":"fluorouracil-adrucil","phase":"phase_3","mechanism":"Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"HCTZ monotherapy","genericName":"HCTZ monotherapy","slug":"hctz-monotherapy","phase":"phase_3","mechanism":"HCTZ (hydrochlorothiazide) is a thiazide diuretic that reduces blood pressure by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the kidney.","indications":["Hypertension","Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease"],"catalyst":""},{"name":"IDO1 Inhibitor","genericName":"IDO1 Inhibitor","slug":"ido1-inhibitor","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Idhifa","genericName":"ENASIDENIB","slug":"enasidenib","phase":"marketed","mechanism":"Idhifa works by blocking the IDH2 enzyme, which is mutated in some AML cells, to prevent the production of a toxic metabolite that promotes cancer growth.","indications":["Acute myeloid leukemia, disease"],"catalyst":""},{"name":"Infliximab (INF) + MTX, DB","genericName":"Infliximab (INF) + MTX, DB","slug":"infliximab-inf-mtx-db","phase":"phase_3","mechanism":"Infliximab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling, while methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) that inhibits folate metabolism and immune cell proliferation.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Inrebic","genericName":"FEDRATINIB HYDROCHLORIDE","slug":"fedratinib-hydrochloride","phase":"marketed","mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs.","indications":["Myelofibrosis","Post-essential thrombocythaemia myelofibrosis","Post-polycythaemia vera myelofibrosis","Primary myelofibrosis"],"catalyst":""},{"name":"Intravenous (IV) abatacept","genericName":"Intravenous (IV) abatacept","slug":"intravenous-iv-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Irbesartan monotherapy","genericName":"Irbesartan monotherapy","slug":"irbesartan-monotherapy","phase":"phase_3","mechanism":"Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","indications":["Hypertension","Diabetic nephropathy in patients with type 2 diabetes and hypertension"],"catalyst":""},{"name":"Irbesartan/HCTZ","genericName":"Irbesartan/HCTZ","slug":"irbesartan-hctz","phase":"phase_3","mechanism":"Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume.","indications":["Hypertension (high blood pressure)","Reduction of cardiovascular events in hypertensive patients at high risk"],"catalyst":""},{"name":"Iza-bren","genericName":"Iza-bren","slug":"iza-bren","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Kinevac®","genericName":"Kinevac®","slug":"kinevac","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lamivudine/Zidovudine","genericName":"Lamivudine/Zidovudine","slug":"lamivudine-zidovudine","phase":"marketed","mechanism":"This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Lopinavir/ritonavir + tenofovir + nucleoside","genericName":"Lopinavir/ritonavir + tenofovir + nucleoside","slug":"lopinavir-ritonavir-tenofovir-nucleoside","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Megace","genericName":"MEGESTROL ACETATE","slug":"megestrol-acetate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Anorexia from HIV","Cachexia due to HIV","Endometrial carcinoma","Hormone receptor positive malignant neoplasm of breast","Nutritional deficiency associated with AIDS"],"catalyst":""},{"name":"Metacillin","genericName":"meticillin","slug":"meticillin","phase":"marketed","mechanism":"","indications":["Bacterial septicemia","Infection of skin AND/OR subcutaneous tissue","Sinusitis","Staphylococcal pneumonia"],"catalyst":""},{"name":"NKTR-214","genericName":"NKTR-214","slug":"nktr-214","phase":"phase_3","mechanism":"NKTR-214 is an engineered interleukin-2 (IL-2) cytokine that preferentially activates and expands CD8+ T cells and NK cells to enhance anti-tumor immune responses.","indications":["Metastatic melanoma (in combination with nivolumab)","Renal cell carcinoma (in combination with nivolumab)","Non-small cell lung cancer (in combination with nivolumab)"],"catalyst":""},{"name":"Nitroglycerin (NTG)","genericName":"Nitroglycerin (NTG)","slug":"nitroglycerin-ntg","phase":"marketed","mechanism":"Nitroglycerin is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and dilate blood vessels, reducing cardiac preload and afterload.","indications":["Acute angina pectoris (sublingual/spray formulation)","Chronic stable angina (long-acting formulations)","Acute myocardial infarction","Heart failure with pulmonary edema"],"catalyst":""},{"name":"Nivolumab and rHuPH20","genericName":"Nivolumab and rHuPH20","slug":"nivolumab-and-rhuph20","phase":"phase_3","mechanism":"Nivolumab blocks PD-1 on immune cells to restore anti-tumor immunity, while rHuPH20 (recombinant human hyaluronidase) enhances drug penetration into tumors by degrading the hyaluronic acid-rich extracellular matrix.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Nivolumab in combination with Ipilimumab","genericName":"Nivolumab in combination with Ipilimumab","slug":"nivolumab-in-combination-with-ipilimumab","phase":"marketed","mechanism":"Nivolumab and ipilimumab together block two different immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses.","indications":["Metastatic melanoma","Advanced renal cell carcinoma","Metastatic non-small cell lung cancer","Malignant pleural mesothelioma","Hepatocellular carcinoma"],"catalyst":""},{"name":"Nivolumab-relatlimab FDC","genericName":"Nivolumab-relatlimab FDC","slug":"nivolumab-relatlimab-fdc","phase":"phase_3","mechanism":"This fixed-dose combination blocks both PD-1 and LAG-3 checkpoints on immune cells, releasing dual brakes on anti-tumor immunity.","indications":["Melanoma (advanced or metastatic)","Non-small cell lung cancer"],"catalyst":""},{"name":"Nivolumab/rHuPH20","genericName":"Nivolumab/rHuPH20","slug":"nivolumab-rhuph20","phase":"phase_3","mechanism":"Nivolumab is a PD-1 inhibitor that blocks immune checkpoint signaling, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous drug delivery and bioavailability.","indications":["Metastatic melanoma","Non-small cell lung cancer","Renal cell carcinoma","Hodgkin lymphoma","Squamous cell carcinoma of the head and neck"],"catalyst":""},{"name":"Nulojix","genericName":"Nulojix","slug":"nulojix","phase":"marketed","mechanism":"T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86","indications":["Renal transplant rejection"],"catalyst":""},{"name":"Nulojix","genericName":"BELATACEPT","slug":"belatacept","phase":"marketed","mechanism":"Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response.","indications":["Renal transplant rejection"],"catalyst":""},{"name":"OPDIVO QVANTIG","genericName":"HYALURONIDASE-NVHY","slug":"hyaluronidase-nvhy","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Open-label Abatacept","genericName":"Open-label Abatacept","slug":"open-label-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Orencia","genericName":"Orencia","slug":"orencia","phase":"marketed","mechanism":"T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86","indications":["Juvenile idiopathic arthritis","Rheumatoid arthritis"],"catalyst":""},{"name":"Ortho Tri-Cyclen LO","genericName":"Ortho Tri-Cyclen LO","slug":"ortho-tri-cyclen-lo","phase":"marketed","mechanism":"Ortho Tri-Cyclen LO is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of norgestimate and ethinyl estradiol.","indications":["Contraception (pregnancy prevention)","Acne vulgaris (FDA-approved indication)"],"catalyst":""},{"name":"PLA + MTX switched to ABA+ MTX, DB","genericName":"PLA + MTX switched to ABA+ MTX, DB","slug":"pla-mtx-switched-to-aba-mtx-db","phase":"phase_3","mechanism":"Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX).","indications":["Rheumatoid arthritis (as part of combination therapy with MTX)","Polyarticular juvenile idiopathic arthritis"],"catalyst":""},{"name":"Panolosetron","genericName":"Panolosetron","slug":"panolosetron","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pemexetred","genericName":"Pemexetred","slug":"pemexetred","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo (PLA) + MTX, DB","genericName":"Placebo (PLA) + MTX, DB","slug":"placebo-pla-mtx-db","phase":"phase_3","mechanism":"This is a control arm combining placebo with methotrexate (MTX), a disease-modifying antirheumatic drug that inhibits dihydrofolate reductase and reduces inflammation.","indications":["Rheumatoid arthritis (as part of control arm in Phase 3 trial)"],"catalyst":""},{"name":"Placebo for Ipilimumab","genericName":"Placebo for Ipilimumab","slug":"placebo-for-ipilimumab","phase":"phase_3","mechanism":"This is a placebo for Ipilimumab, meaning it has no active therapeutic effect.","indications":["Metastatic melanoma"],"catalyst":""},{"name":"Placebo for Nivolumab","genericName":"Placebo for Nivolumab","slug":"placebo-for-nivolumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trials of Nivolumab"],"catalyst":""},{"name":"Placebo for apixaban","genericName":"Placebo for apixaban","slug":"placebo-for-apixaban","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in apixaban clinical trials (specific indication depends on parent trial)"],"catalyst":""},{"name":"Placebo matching BMS-790052","genericName":"Placebo matching BMS-790052","slug":"placebo-matching-bms-790052","phase":"phase_3","mechanism":"BMS-790052 is a direct-acting antiviral agent that inhibits hepatitis C virus (HCV) NS5A protein, blocking viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1)"],"catalyst":""},{"name":"Placebo matching Dacarbazine","genericName":"Placebo matching Dacarbazine","slug":"placebo-matching-dacarbazine","phase":"phase_3","mechanism":"This is a placebo control arm matching the active comparator dacarbazine, containing no active pharmaceutical ingredient.","indications":["Control arm in Phase 3 trial (specific indication unknown without trial protocol)"],"catalyst":""},{"name":"Placebo matching Ipilimumab","genericName":"Placebo matching Ipilimumab","slug":"placebo-matching-ipilimumab","phase":"phase_3","mechanism":"This is a placebo control arm matching the dosing and administration schedule of ipilimumab, the active comparator.","indications":["Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens"],"catalyst":""},{"name":"Placebo matching Ribavirin","genericName":"Placebo matching Ribavirin","slug":"placebo-matching-ribavirin","phase":"phase_3","mechanism":"This is a placebo control matching the appearance and dosing schedule of ribavirin, an antiviral nucleoside analog that inhibits viral RNA synthesis.","indications":["Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design)"],"catalyst":""},{"name":"Placebo matching with Abatacept","genericName":"Placebo matching with Abatacept","slug":"placebo-matching-with-abatacept","phase":"marketed","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Placebo matching with Metformin IR","genericName":"Placebo matching with Metformin IR","slug":"placebo-matching-with-metformin-ir","phase":"marketed","mechanism":"This is a placebo-matched formulation used in clinical trials to maintain blinding while comparing against Metformin IR (immediate-release), which reduces hepatic glucose production and improves insulin sensitivity.","indications":["Used as control arm in clinical trials for type 2 diabetes or related metabolic disorders"],"catalyst":""},{"name":"Placebo matching with Metformin XR","genericName":"Placebo matching with Metformin XR","slug":"placebo-matching-with-metformin-xr","phase":"marketed","mechanism":"This is a placebo formulation matched to Metformin XR for use as a control in clinical trials, containing no active pharmaceutical ingredient.","indications":["Clinical trial control for studies evaluating Metformin XR efficacy and safety"],"catalyst":""},{"name":"Prenisolone","genericName":"Prenisolone","slug":"prenisolone","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Regorafinib","genericName":"Regorafinib","slug":"regorafinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Reyataz","genericName":"ATAZANAVIR","slug":"atazanavir","phase":"marketed","mechanism":"Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Ribasphere","genericName":"Ribasphere","slug":"ribasphere","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ritonavir (heat-stable)","genericName":"Ritonavir (heat-stable)","slug":"ritonavir-heat-stable","phase":"marketed","mechanism":"Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","indications":["HIV-1 infection (in combination with other antiretroviral agents)","Pharmacokinetic booster for other protease inhibitors"],"catalyst":""},{"name":"SAR302503","genericName":"SAR302503","slug":"sar302503","phase":"phase_3","mechanism":"SAR302503 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"Subcutaneous (SC) abatacept","genericName":"Subcutaneous (SC) abatacept","slug":"subcutaneous-sc-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Adult-onset Still's disease"],"catalyst":""},{"name":"Sustiva","genericName":"Sustiva","slug":"sustiva","phase":"marketed","mechanism":"Cholesterol 24-hydroxylase, ATP-binding cassette sub-family G member 2, Nuclear receptor subfamily 1 group I member 2","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Sustiva","genericName":"EFAVIRENZ","slug":"efavirenz","phase":"marketed","mechanism":"Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Thalomid","genericName":"THALIDOMIDE","slug":"thalidomide","phase":"marketed","mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth.","indications":["Newly Diagnosed Multiple Myeloma","Acute Treatment of Moderate to Severe ENL","Maintenance Therapy for ENL Recurrence"],"catalyst":""},{"name":"Treatment A: Mavacamten intact oral capsule","genericName":"Treatment A: Mavacamten intact oral capsule","slug":"treatment-a-mavacamten-intact-oral-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Videx","genericName":"DIDANOSINE","slug":"didanosine","phase":"marketed","mechanism":"Small molecule","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Yervoy","genericName":"Yervoy","slug":"yervoy","phase":"marketed","mechanism":"Cytotoxic T-lymphocyte protein 4","indications":["High grade squamous intraepithelial neoplasia of esophagus","Metastatic malignant melanoma","Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","Microsatellite instability-high colorectal cancer","Renal cell carcinoma"],"catalyst":""},{"name":"abatacept (ABA)","genericName":"abatacept (ABA)","slug":"abatacept-aba","phase":"marketed","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"efavirenz, stavudine extended release, lamivudine","genericName":"efavirenz, stavudine extended release, lamivudine","slug":"efavirenz-stavudine-extended-release-lamivudine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"or Glyburide alone.","genericName":"or Glyburide alone.","slug":"or-glyburide-alone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"or Metformin HCl alone","genericName":"or Metformin HCl alone","slug":"or-metformin-hcl-alone","phase":"marketed","mechanism":"Metformin HCl reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.","indications":["Type 2 diabetes mellitus","Prediabetes (off-label or prevention studies)","Polycystic ovary syndrome (PCOS) with insulin resistance"],"catalyst":""},{"name":"panHer","genericName":"panHer","slug":"panher","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"stavudine, efavirenz, lamivudine","genericName":"stavudine, efavirenz, lamivudine","slug":"stavudine-efavirenz-lamivudine","phase":"phase_3","mechanism":"This is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase.","indications":["HIV-1 infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQNEZxZlZBT25yRkItX05hcFc0am0tem1VbmhwVlpOcWJaYlFxLWs1bUVKc1hnLUh4dkFhejdkNW5xM011RkZpa0NRdEx4aE03ZWFRcnk3aFBHbmNrQlRUSUhHVWluTjZoS09sSXhNdGhwVkhhQkJHbUFISXdoQnFBRklfWkhJV2k2TXdlbmIzU0NPcG8tZWxxZmpLVC1ESWN6dGp0eUlnTzFuQ0lzYkNjWUMtcGlIUi1hTWc?oc=5","date":"2026-04-08","type":"pipeline","source":"AD HOC NEWS","summary":"Bristol-Myers Squibb Company stock: What you should know now - AD HOC NEWS","headline":"Bristol-Myers Squibb Company stock: What you should know now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPWmR1RlE4MlM3bjhwejhVZUNEdUtNbzZndXZUYXlQRmR6eEpwbWFWTTM3NWlVS0N5UmFaOUtPYUNQWHhhaXYxWXNaNWNxMFh4OTE5aUFfVkg0QVpYc1oyWnZvTkx1U3lwb1F4QTdvRGR6UFJWNHJNS2JQU2F4MHJiNlI4YlRpbHZ2amFiMWVlNWdjVDN1Y2lvZ0QtT0xOM0xUSnRCc1JLaHlGSlBzVzBValZXN0pOS2I1ZmhTUDRCcU9KU3N2clZtd3BIbl93MUpNaU1XMDJfTGIxU3lXZ3pQak5QNHBYS2I4TldRbnpJTUF4WFM1SDI5NzNaazVLdzMtQWhOYWRnWkRSV3I4TFE?oc=5","date":"2026-04-07","type":"pipeline","source":"The Corner .eu","summary":"Rovi completes acquisition of pharmaceutical manufacturing plant in Phoenix, Arizona, following execution of agreement with Bristol Myers Squibb - The Corner .eu","headline":"Rovi completes acquisition of pharmaceutical manufacturing plant in Phoenix, Arizona, following execution of agreement w","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQVlZmM3hKUVRqX2duZFJna2RmWkdpUzVFZjNHZWplMnRHVVVqSHE5NG1vUldNaEx2ZjhoOW13cWtNWkg5NkJ6Y0ptVTMzeTc1eDBkWHUwTHpseVRVSDI3T0xXeFNhS1ktX2RlMmphZVJiNXQ5aF9zQnV0Y29kdHNJWUdQdnFDWVJmSXFSZ1p5ZXBRRmJTTHBfaE9vX0k4a0RadjBDZzNSeFRZSEpwYTNNc1lWRzFudlg1NWFKbEFQaW5ZY3YyYmFnRGg0RXJFMjVrR2prSmt0MU1PeVZxYW5uUTZLa2ZKT3QyQ3dRLUs2Vm5qRzFmeXVhT1JWejBmeERaQkFsQ21ub1FEM0FHeEotc2dEbk14U2d2ZWlOOGg4RTRVRS1pLVZDLU54YlR0TVkxTTdJZVpqWDNqSDlvY3UtY2s0R1A4eFlj?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Bar","headline":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi,","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"simplywall.st","summary":"A Look At Bristol Myers Squibb (BMY) Valuation After US Tariff Threats Hit Pharma Stocks - simplywall.st","headline":"A Look At Bristol Myers Squibb (BMY) Valuation After US Tariff Threats Hit Pharma Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZkJwM0VrdHp3UEpMLWhVTTdsczUyNFhTano2VTB2R3VJcjhxa1p5N19DaFdvMGRieTRCQ0diTFVGMm1iMlp5empQUlJNWXREdTZPLWhnaUliQXRac2NJZllieUZqd21ESi00QUstVmhzM0t6RnNZSE5QVnhuS04ycjVYZEVJVE1NY1lFMmJwVkw2VFBPR19ad3QxaEpyLVhYTmtjeDZRSWw?oc=5","date":"2026-04-03","type":"deal","source":"The Business Journals","summary":"Spanish pharma firm enters Phoenix market after deal with Bristol Myers Squibb - The Business Journals","headline":"Spanish pharma firm enters Phoenix market after deal with Bristol Myers Squibb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQQ09QRFNDMHkxYlo3NkZBaVN5Z0p1QjhIb0V0WF9PNUtpRjZKXzFONnpiME9za19IeXN4b0ZYN0hfNGhpbFY2T3pOZzhhYXhhNkVHbDBQM2gyelZ3TG1sTGhCdHVPb0pMc08zQ2cyZXFnTGhCQThMR09fcUFNQ3RaMTVoSkNLLWt6LXRVTUEySmZZNENVMjZYQnF6NkxYZ1dneTd6Tkg1bGV2Zjg?oc=5","date":"2026-04-03","type":"pipeline","source":"Yahoo Finance","summary":"AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know - Yahoo Finance","headline":"AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNRVNVU2FSQ0lHSkQ5eVBDbDhYaU80bmZDOE5FSDRwRGpKaDU4elg3S3ZRNTJJX1FKTTQwa21yYXVxME9NVl9pMDdNQjJNVlVGT1l5VFBTTTFpWWFSdllNbkw0VU1QS0lnU1VoVjJrb0NGamhrWlpZMkRxLUVZTThaSmhoNV92VFpmZzh3MHBVY3EtV25q?oc=5","date":"2026-03-31","type":"trial","source":"Fierce Biotech","summary":"BMS links up with Faro to use AI to improve clinical trial protocols - Fierce Biotech","headline":"BMS links up with Faro to use AI to improve clinical trial protocols","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE05eFpyQm54ZExiQXJQbXdEeTJ2UndoZFZqV21samVvOW1POVNfa1E3bnhvWW9zWjVIQUZVZEVLRmg5cE56dEZKcURyZHotbGsxV19kUkZBRFdoblNBU2FjTzA0TVZQb1R1czNycVN6d1NMdw?oc=5","date":"2026-03-17","type":"patent","source":"Labiotech.eu","summary":"Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff? - Labiotech.eu","headline":"Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNMmlVSVBuRkxFdXVWQW56YUJaUDhLbjZtWTVmSDNYcjVpUWh2bHY0cWY0bU45UmtXX1dFa0h4cjRHLXZSd0czSjJxWndHOFRpbVlkZG9sQ3BYU3RaVXpFMjk1Z1ljUlNUTmsyQnByS2VsNDhfYmtSOTBXZUlsNkM1RDJDV20yMkJOT3NNWERmUVZpRkNtbWFpRnVDaVc?oc=5","date":"2026-02-02","type":"pipeline","source":"statnews.com","summary":"Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s - statnews.com","headline":"Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQLUQ3Qm1UaDNMM2FiaEdtanFTdWZDOXhkdk9WMENXMkZySHUwWnB6YUU1Q191QjhkSzJwQl9UZmh5bnZISHdaLTRZQzJWT1ZOX0tocThwZl9Bd2ROcFJKb1cyT3BZMjFsSjU2RWt1aUY0U1lfVTl3Z3lFOVhQZ3N3c3JEdjJLcXBiMjVHZGdPRjdpMVFKV2h0NElpOVBnRnZkeGxEYW42NFRlR1NvM1M2cWkwVTI3S3hqc2prNjdRaXk2bEt5d1g2ZHczUnFKN3ZNcEZyaDd5bUU?oc=5","date":"2026-01-20","type":"deal","source":"Reuters","summary":"Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters","headline":"Bristol Myers partners with Microsoft for AI-driven lung cancer detection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPeDBobm0zTjI0MFZ6aUN3Y0JlR29qWG04TzdFZUtac1hMaHNSNkVmQVQ4OXpUcTFfZFR1VHFtOFc0blVSMUVFdEtDQUFDZXpUdE1BeWY0TENyVEhta3VmclVyc0w1d1FwanpudktuLVdxc244bmo1R2c1N1lRMDU3Z0dGcjhqTWtwNncxSEI4UGlKY2pyaVhCNGdOSk9DVEZsUjlUY3ZR?oc=5","date":"2025-11-14","type":"pipeline","source":"Bristol Myers Squibb","summary":"Veterans redefining manufacturing leadership in pharma - Bristol Myers Squibb","headline":"Veterans redefining manufacturing leadership in pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWF9oRU9sOWFGcTNfWGFqNHNPaEFvalhjbnhqWURVb3hEbnVFblVoSENoMmthbVlBbHA3NHc2NlZaQVlXVDlCOWhFSDFCSFlmWkxZaEYzVTBRamxpaUVsSXhxalhPMU5XVkxlUk11UV9TWEpIdWVqQU5sTHJVTWFlNWhua1FIay14OUZrSEctYTloN3RxRDMtcG00ODM1WDVoMGlPNWpyY2pqa3lrUFE?oc=5","date":"2025-09-15","type":"pipeline","source":"Fierce Pharma","summary":"BMS sells controlling stake in historic US-China pharmaceutical joint venture - Fierce Pharma","headline":"BMS sells controlling stake in historic US-China pharmaceutical joint venture","sentiment":"neutral"}],"patents":[{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"8148356","type":"Formulation","expiryDate":"2026-05-21","territory":"US","genericFilings":[]},{"drugName":"Vidaza","drugSlug":"azacitidine","patentNumber":"12053482","type":"Method of Use","expiryDate":"2029-05-14","territory":"US","genericFilings":[]},{"drugName":"Vidaza","drugSlug":"azacitidine","patentNumber":"11571436","type":"Formulation","expiryDate":"2029-05-14","territory":"US","genericFilings":[]},{"drugName":"Vidaza","drugSlug":"azacitidine","patentNumber":"8846628","type":"Formulation","expiryDate":"2030-06-03","territory":"US","genericFilings":[]},{"drugName":"Eliquis","drugSlug":"apixaban","patentNumber":"9326945","type":"Formulation","expiryDate":"2031-02-24","territory":"US","annualRevenue":14443000000,"genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"9327028","type":"Method of Use","expiryDate":"2031-07-21","territory":"US","genericFilings":[]},{"drugName":"Eliquis","drugSlug":"apixaban","patentNumber":"9326945*PED","type":"Compound","expiryDate":"2031-08-24","territory":"US","annualRevenue":14443000000,"genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"8722738","type":"Method of Use","expiryDate":"2032-04-06","territory":"US","genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"8747894","type":"Formulation","expiryDate":"2032-05-08","territory":"US","genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"9561204","type":"Method of Use","expiryDate":"2032-05-08","territory":"US","genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"9427421","type":"Formulation","expiryDate":"2032-05-08","territory":"US","genericFilings":[]}],"drugCount":181,"phaseCounts":{"marketed":75,"discontinued":2,"phase_2":36,"phase_3":54,"phase_1":14},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}